Sudarshan Pharma Approves 9.5% MedTherapy Biotechnology Stake Acquisition

5 September 2026

Sudarshan Pharma Industries Ltd.

Provides integrated CAR-T cell gene therapy CDMO and cancer treatments.

Recent Events

Sudarshan Pharma Promoters Pledge 66.5 Lakh Shares Each To Satin Finserv

Sudarshan Pharma Industries Promoters Pledge 1.32 Crore Shares To Satin Finserv

Sudarshan Pharma Converts USD1.5 Million FCCBs Into 48.1 Lakh Shares

Sudarshan Pharma Creates 3.25% Promoter Pledge To Secure Company Loan

Sudarshan Pharma Allots 90 Lakh Shares on Promoter Warrant Conversion

Get features of